Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 552-562

  Roepman, Paul ^a   Schlicker, Andreas ^b   Tabernero, Josep ^c   Majewski, Ian ^b   Tian, Sun ^a   Moreno, Victor ^d,e   Snel, Mireille H ^a   Chresta, Christine M ^f   Rosenberg, Robert ^g   Nitsche, Ulrich ^g   Macarulla, Teresa ^c   Capella, Gabriel ^e   Salazar, Ramon ^e   Orphanides, George ^f   Wessels, Lodewyk F A ^b,h   Bernards, Rene ^a,b   Simon, Iris M ^a  

^a Agendia NV   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f ASTRAZENECA   (United Kingdom)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

chemotherapy benefit; colorectal cancer; EMT; mismatch repair; molecular subtypes

Indexed keywords

B RAF KINASE; FLUOROURACIL; MOLECULAR MARKER;

AGED; ARTICLE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84887989710     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28387     Document Type: Article

References (34)

1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-83.
2. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
3. Kinzler KW, Vogelstein B,. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
4. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-61.
5. Sinicrope FA, Sargent DJ,. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012; 18: 1506-12.
6. Miquel C, Jacob S, Grandjouan S, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 2007; 26: 5919-26.
7. Roth AD, Tejpar S, Delorenzi M, et al. Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
8. Warusavitarne J, Schnitzler M,. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 2007; 22: 739-48.
9. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11.
10. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
11. Higgins MJ, Baselga J,. Targeted therapies for breast cancer. J Clin Invest 2011; 121: 3797-803.
12. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-6.
13. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
14. Loboda A, Nebozhyn MV, Watters JW, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics 2011; 4: 9.
15. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012; 12: 260.
16. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
17. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for stage II colon cancer patients. Ann Surg 2013; 257: 1053-8.
18. Tian S, Roepman P, Popovici V, et al. A robust genomic signature for detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. J Pathol 2012; 228: 586-95.
19. Vilar E, Gruber SB,. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010; 7: 153-62.
20. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology-colorectal cancer screening. Version 2. 2012. Available from: http://www.nccn.org/professionals/physician-gls/pdf/colorectal-screening. pdf.
21. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-7.
22. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
23. Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12 (14 Pt 1): 4147-53.
24. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247257.
25. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
26. González-García I, Moreno V, Navarro M, et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 2000; 92: 544-9.
27. Bates RC, Mercurio AM,. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 2005; 4: 365-70.
28. Oh SC, Park YY, Park ES, et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012; 61: 1291-8.
29. Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19: 899-909.
30. Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2: 59-64.
31. Duthaler R, Gerspacher M, Holzer P, et al. Inventors; Novartis AG, Assignee. Pyrimidine derivatives. United States patent US 6885550. 2010 Jan 14.
32. Kato-Nakano M, Suzuki M, Kawamoto S, et al. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. Anticancer Res 2010; 30: 4555-62.
33. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-400.
34. Gotink KJ, Verheul HM,. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010; 13: 1-14.